EVANSTON, Ill.--(BUSINESS WIRE)--Minute Molecular Diagnostics today announced that the U.S. Food and Drug Administration (FDA) granted an Emergency Use Authorization (EUA) for its rapid DASH ...
The Canada Point of Care Molecular Diagnostics Market, valued at USD 350 million in 2024, is projected to reach USD 560 ...
The FDA has issued its first emergency use authorization for a COVID-19 molecular diagnostic test that does not require a prescription and can be used at home. Developed by Cue Health, the Cue ...
Home diagnostics company Cue Health announced its received FDA de novo authorization for its at-home COVID-19 test, dubbed the Cue COVID-19 Molecular Test. The Cue COVID-19 Molecular Test detects ...
New partnership enables a free Sesame telehealth consultation with purchase of a Lucira at-home COVID-19 test, providing a full test-to-treat experience from the comfort of home, within two hours NEW ...
3EO becomes the first point-of-care molecular technology to be retail priced below $15 per test. 3EO adds a breakthrough business model enabling more physician practices to upgrade technology from ...
San Diego-based medical tech company, Cue Health, bragged about receiving an industry-first De Novo authorization from the U.S. Food and Drug Administration (FDA) for its at-home COVID-19 test kit.
The U.S. Food and Drug Administration told consumers Monday to throw out any at-home COVID-19 tests made by San Diego biotech Cue Health, because they could give users false results. Early in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results